Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Clinical trial finds RNA inhibitor effectively reduces 'bad cholesterol' in patients with cardiovascular disease
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
New Scientist3d
CAR T-cell therapy could help prevent clogged arteries
Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...